[1]郑福利,张颖,王建.血清S100A6检测对卵巢上皮性癌的诊断价值[J].现代检验医学杂志,2015,30(05):22-23.[doi:10.3969/j.issn.1671-7414.2015.05.007]
　ZHENG Fu-li,ZHANG Ying,WANG Jian.Study on Diagnostic Value of Detecting Serum S100A6 in the Epithelial Ovarian Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(05):22-23.[doi:10.3969/j.issn.1671-7414.2015.05.007]
点击复制

血清S100A6检测对卵巢上皮性癌的诊断价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年05期
页码:
22-23
栏目:
论著
出版日期:
2015-12-10

文章信息/Info

Title:
Study on Diagnostic Value of Detecting Serum S100A6 in the Epithelial Ovarian Carcinoma
作者:
郑福利1; 张颖2; 王建3
1.陕西中医学院第二附属医院妇产科，陕西咸阳712000； 2.解放军第三二三医院妇产科，西安710054；3.第四军医大学西京医院妇产科，西安710032
Author(s):
ZHENG Fu-li1; ZHANG Ying2; WANG Jian3
1.Department of Gynecology and Obstetrics，the Second Affiliated Hospital of Shaanxi College of Traditional Chinese Medicine，Shaanxi Xianyang 712000，China；2．Department of Gynecology and Obstetrics,PLA 323 Hospital，Xi’an 710054，China；3.Department of Gynecology and Obstetrics，Xijing Hospital of Fourth Military Medical University，Xi’an 710032，China
关键词:
卵巢癌; 钙结合蛋白S100A6; 临床诊断
分类号:
R737.31；R730.43
DOI:
10.3969/j.issn.1671-7414.2015.05.007
文献标志码:
A
摘要:
目的探讨血清S100A6对卵巢上皮性癌的诊断及疾病进展临床诊断的指导价值。方法采用酶联免疫吸附测定法(ELISA)检测40例卵巢上皮性癌患者、20例卵巢良性肿瘤患者及20例正常体检者血清中S100A6的浓度。结果卵巢癌与良性卵巢肿瘤，正常对照患者相比，S100A6血清浓度显著升高，差异具有统计学意义(t=2.66，P<0.01)。中晚期(Ⅲ+Ⅳ期)卵巢癌患者S100A6血清浓度显著高于早期(Ⅰ+Ⅱ期)卵巢癌患者(t=4.68，P<0.001)。与高分化和中分化相比，低分化的卵巢癌患者S100A6血清浓度显著升高，差异有统计学意义(t=2.49，P<0.05)。出现淋巴结转移的卵巢癌患者中S100A6血清浓度显著高于淋巴结无转移的卵巢癌患者(t=4.02，P<0.01)。S100A6血清平均浓度与病理类型无关(t=1.8，P＞0.05)。结论血清S100A6的血清浓度与卵巢癌病情发展相关，S100A6有望成为监测卵巢上皮性癌病情发展的分子标志物。
Abstract:
ObjectiveTo investigate the significance of serum S100A6 in epithelial ovarian carcinoma and explore the correlation between the serum S100A6 and clinicopathologic features．MethodsThe serum S100A6 level in 40 patients with epithelial ovarian carcinoma and 20 benign ovarian tumor group ，20 normal control group were measured by enzyme-linked immunosorbent assay (ELISA)．ResultsThe serum S100A6 level was significantly higher in the EOC group than in the benign ovarian tumor group and normal control group (t=2.66，P<0.01)．The serum S100A6 level was obviously increased in advanced stage EOC patients compared with early stage EOC patients (t=4.68，P<0.001)．The serum S100A6 level was significantly higher in the poor-differentiated group than in the well-differentiated group and moderate-differentiated group (t=2.49，P<0.05)．The serum S100A6 level in lymph node metastasis was obviously higher than nolymph node metastasis in EOC patients (t=4.02，P<0.01)．The serum S100A6 level was no difference between seroustype and other spathological type (t=1.8，P＞0.05)．ConclusionThe data suggested that serum S100A6 level can indicate the progression of epithelial ovarian carcinoma，and may be a new promising approach in targeting therapy of ovarian cancer．

参考文献/References:

［1］Zhu L，Kohda F，Nakahara T，et al．Aberrant expression of S100A6 and matrix metalloproteinase 9，but not S100A2，S100A4，and S100A7，is associated with epidermal carcinogenesis［J］．Journal of Dermatological Science，2013，72(3)：311-319．
[2]Guo ZH， Zhang J， Liang Y，et al．Analyzing S100A6 expression in endoscopic ultrasonography-guided fine-needle aspiration specimens：a promising diagnostic method of pancreatic cancer［J］．Journal of Clinical Gastroenterology，2013，47(1)：69-75．
[3]Wang XH，Zhang LH，Zhong XY，et al．S100A6 overexpression is associated with poor prognosis and is epigenetically up-regulated in gastric cancer［J］．American Journal of Pathology，2010，177(2)：586-597．
[4]Wei BR，Hoover SB，Ross MM，et al．Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients［J］．PLoS One，2009，4(10)：e7670．
[5]黄海力，吴本俨，朱旭东，等.胃癌及其转移灶中S100A6基因的表达［J］．中华肿瘤杂志，2008，30(7)：506-510． Huang HL， Wu BY， Zhu XD，et al．Expression of S 100A6 in primary and metastatic human gastric cancer［J］．Chinese Journal Oncology，2008，30(7)：506-510．
[6]De Petris L，Orre LM，Kanter L，et al．Tumor expre-ssion of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer［J］．Lung Cancer，2009，63(3)：410-417．
[7]McKiernan E，McDermott EW，Evoy D，et al．The ro-le of S100 genes in breast cancer progression［J］．Tumour Biology，2011，32(3)：441-450．
[8]Ito T， Yoshida H， Tomoda C，et al．Expression of S 100A2 and S100A6 in thyroid carcinomas［J］．Histopathology，2005，46(5)：569-575．
[9]Ishii A， Suzuki M，Satomi K．Increased cytoplasmic S100A6 expression is associated with pulmonary adenocarcinoma progression［J］．Pathology International，2009，59(9)：623-630．
[10]Luo X，Sharff KA，Chen J，et al．S100A6 expression and function in human osteosarcoma［J］．Clinical Orthopaedics and Related Research，2008，466(9)：2060-2070．
[11]Vimalachandran D， Greenhalf W， Thompson C，et al．High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients［J］．Cancer Research，2005，65(8)：3218-3225．
[12]Salama I，Malone PS，Mihaimeed F，et al．A review of the S100 proteins in cancer［J］．European Journal of Surgical Oncology，2008，34(4)：357-364．
[14]Luu HH，Zhou L，Haydon RC，et al．Increased expr-ession of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma［J］．Cancer Letters，2005，229(1)：135-148．
[15]Maelandsmo GM，Florenes VA，Mellingsaeter T，et al．Differential expression patterns of S100A2，S100A4 and S100A6 during progression of human malignant melanoma［J］．Int J Cancer，1997，74(4)：464-469．
[16]郑福利，张颖，赵亚宁，等．S100A6 siRNA对卵巢癌细胞生物学行为的影响［J］．中国妇幼健康研究，2014，25(1)：48-51． Zheng FL， Zhang Y， Zhao YN，et al．Influence of S100A6 siRNA on biological features of human ovarian cancer cell［J］．Chinese Journal of Woman and Child Health Research，2014，25(1)：48-51．

相似文献/References:

[1]顾益凤,朱自力,张金业,等.利用ROC曲线选择血清HE-4对卵巢癌的最佳诊断界点[J].现代检验医学杂志,2015,30(04):141.[doi:10.3969/j.issn.1671-7414.2015.04.043]
　GU Yi-feng,ZHU Zi-li,ZHANG Jin-ye,et al.Selecting the Best Cut-off Point of Serum HE-4 in Ovarian Cancer by ROC Curve[J].Journal of Modern Laboratory Medicine,2015,30(05):141.[doi:10.3969/j.issn.1671-7414.2015.04.043]
[2]詹颉,常宁宁,李小侠,等.CEA，AFP，CA125，CA199和CA72-4联合检测在鉴别卵巢良恶性疾病中的应用价值[J].现代检验医学杂志,2015,30(05):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
　ZHAN Jie,CHANG Ning-ning,LI Xiao-xia,et al.Clinical Value of Combined Detection of CEA，AFP，CA125，CA199 and CA72-4 in the Identification of Ovarian Benign and Malignant Disease[J].Journal of Modern Laboratory Medicine,2015,30(05):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
[3]邢瑞青,吴永昌,陈慧昱,等.血清CA125,HE4及ROMA指数对卵巢癌诊断价值的临床研究[J].现代检验医学杂志,2016,31(06):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
　XING Rui-qing,WU Yong-chang,CHEN Hui-yu,et al.Diagnostic Value of Serum CA125,HE4 and ROMA Index in Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2016,31(05):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
[4]张 悦a,段海霞,暴 蕾a,等.microRNA-125b在葛根素诱导人卵巢癌细胞SKOV3凋亡中的作用研究[J].现代检验医学杂志,2017,32(05):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
　ZHANG Yuea,DUAN Hai-xia,BAO Leia,et al.Role of MicroRNA-125b in Human Ovarian Cancer Cell SKOV3 Induced Apoptosis by Puerarin[J].Journal of Modern Laboratory Medicine,2017,32(05):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
[5]徐金良a,杜丹丹,翟志敏,等.卵巢良恶性肿瘤患者血液NLR,LMR,RDW,PLR四项参数的变化及其临床意义[J].现代检验医学杂志,2018,33(02):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　XU Jin-lianga,DU Dan-dan,ZHAI Zhi-min,et al.Changes and Clinical Significance of Four Parameters of NLR,LMR, RDW and PLR in Patients with Benign and Malignant Ovarian Tumors[J].Journal of Modern Laboratory Medicine,2018,33(05):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[6]马同敏,赵志强.血清CA125,STIP1和IGF-Ⅰ联合检测对卵巢癌的早期诊断价值研究[J].现代检验医学杂志,2018,33(06):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
　MA Tong-min,ZHAO Zhi-qiang.Clinical Value of Combined Detection of Serum CA125,STIP1 and IGF-I Levels in Early Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(05):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
[7]张善弟,荆成宝,禹 梅.血清CEA,CA125和HE4联合检测对卵巢癌的诊断价值[J].现代检验医学杂志,2018,33(06):122.[doi:10.3969/j.issn.1671-7414.2018.06.032]
　ZHANG Shan-di,JING Cheng-bao,YU Mei.Clinical Value of Combined Detection of Serum CEA,CA125 and HE4 in the Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(05):122.[doi:10.3969/j.issn.1671-7414.2018.06.032]
[8]刘 青,邓慧敏,周林涛,等.卵巢癌患者组织中miR-135b的表达及临床意义[J].现代检验医学杂志,2019,34(02):32.[doi:10.3969/j.issn.1671-7414.2019.02.009]
　LIU Qing,DENG Hui-min,ZHOU Lin-tao,et al.Expression and Clinical Significance of miR-135bin Tissues of Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2019,34(05):32.[doi:10.3969/j.issn.1671-7414.2019.02.009]
[9]侯 娟,蒋树立,滕长财.基于TCGA 数据库卵巢癌患者的miR-301b 表达量与生存状况生物信息学分析[J].现代检验医学杂志,2020,35(04):37.[doi:10.3969/j.issn.1671-7414.2020.04.009]
　HOU Juan,JIANG Shu-li,TENG Chang-cai.Bioinformatics Analysis of Mir-301b Expression and Survival Status of Patients with Ovarian Cancer Based on TCGA Database[J].Journal of Modern Laboratory Medicine,2020,35(05):37.[doi:10.3969/j.issn.1671-7414.2020.04.009]
[10]杨立芬,何建清,尹立新,等.人卵巢癌细胞SKOV3中壳多糖酶3样蛋白1的表达和对细胞增殖及侵袭的影响实验研究[J].现代检验医学杂志,2021,36(04):31.[doi:10.3969/j.issn.1671-7414.2021.04.007]
　YANG Li-fen,HE Jian-qing,YIN Li-xin,et al.Expression of Chitinase 3-like Protein 1 in Human Ovarian Cancer Cell Skov3and Its Effect on Cell Proliferation and Invasion[J].Journal of Modern Laboratory Medicine,2021,36(05):31.[doi:10.3969/j.issn.1671-7414.2021.04.007]

备注/Memo

备注/Memo:
收稿日期：2015-05-06修回日期：2015-06-27血清S100A6检测对卵巢上皮性癌的诊断价值基金项目：国家自然科学基金资助项目(NO：81172458)；国家自然科学基金资助项目 (NO：81302243)。 作者简介：郑福利(1978-)，女，硕士，主治医师，主要从事妇产科临床，Tel：18049414376，E-mail：zheng.337700@163.com。 通讯作者：王建(1962-)，男，教授，主任医师，主要从事妇产科临床与基础研究，E-mail：184183102@qq.com。
更新日期/Last Update: 1900-01-01